在中度至重度亚托皮炎的成年人中,Tralokinumab在一年以上的有效性:来自两个III期试验的数据汇总
Eric L Simpson1, Andrew E Pink2, Andrew Blauvelt3
1Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
American journal of clinical dermatology
|September 8, 2023
概括
特拉洛基努马布在一年内在中度至重度的亚托皮性皮炎 (AD) 中表现出持续有效性. 持续治疗显示,阿尔茨海默病患者的皮肤清除和严重程度逐渐改善.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 中度至重度的亚托邦性皮炎 (AD) 构成了重大的治疗挑战.
- 一种IL-13抑制剂特拉洛基努马布在阿尔茨海默病的III期试验中显示出有效性.
- 特拉洛金纽马布的长期治疗效应需要进一步研究.
研究的目的:
- 评估特拉洛金巴治疗中度至重度AD的成年人的长期疗效和耐久性.
- 在52周的时间内评估持续的皮肤清除和症状减少.
主要方法:
- 两项III期试验 (ECZTRA 1和2) 的综合分析,涉及1596名患者.
- 在第16周达到应答的患者被重新随机分为特拉洛金巴 (q2w或q4w) 或安慰剂.
- 预先指定的和特此后的分析评估了研究人员的全球评估 (IGA 0/1) 和湿疹区域和严重性指数 (EASI-75) 评分的维持.
主要成果:
- 在第52周,持续的IGA 0/1反应率为55.9% (q2w),42.4% (q4w) 和34.0% (安慰剂).
- 在第52周的EASI-75持续反应率为57.3% (q2w),50.4% (q4w) 和26.4% (安慰剂).
- 后期分析显示,随着时间的推移,随着持续的特拉洛金努马布治疗,应答率有所改善.
结论:
- 特拉洛金马布在一年内在中度至重度的亚托皮性皮炎中提供渐进和持续的改善.
- 超过16周的持续用特拉洛金纽马布治疗可以提高长期疗效.
- 该药物在阿尔茨海默病管理中显示出有利的长期安全性和有效性.
相关概念视频
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:16Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K
01:19Antiasthma Drugs: Leukotriene Modifiers
343
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
343